This study examines the incidence of and risk factors for venous and arterial thrombosis in patients hospitalized with COVID-19 in 4 New York City hospitals.
Mylan appealed from a Patent Trial and Appeal Board (Board) discretionary denial of institution of an inter partes review (IPR) proceeding. The Board declined to institute Mylan’s IPR.
Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New Vision s arguments were unavailing, however, as the Federal Circuit avoided the issue entirely, ruling last week that the Board s decision be vacated and the case remanded for hearing before a constitutionally properly appointed panel. The basis for this decision is that New Vision had not waived its challenge under
Arthrex, Inc. v. Smith & Nephew, now under review by the Supreme Court. The Federal Circuit s opinion was written by Judge Moore joined by Judge Taranto and in part by Judge Newman, who also dissented-in-part. It is Judge Newman s dissent that is noteworthy, because Judge Newman believed that the question of whether a contract/license between the parties, designating the District of Nevada as the forum for any dispute, should have precluded the PTAB from asserting jurisdiction (and as a threshold issue might have precluded remand if the PTAB had improperly done so). The PTAB, intervenor in this appeal, maintained that the jurisdiction issue was not provided